Reference Citation Analysis: Find an Article, Find a Category, Find a Journal, Find a Scholar

For: Issa AM, Aboushawareb SA, Eisenstat DD, Guilcher GM, Liu G, Rassekh SR, Strahlendorf C, Tallen G, Tanoshima R, Carleton B. Deliberations about clinical pharmacogenetic testing in pediatric oncology. Per Med 2021;18:399-405. [PMID: 33973801 DOI: 10.2217/pme-2020-0120] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]

For:	Issa AM, Aboushawareb SA, Eisenstat DD, Guilcher GM, Liu G, Rassekh SR, Strahlendorf C, Tallen G, Tanoshima R, Carleton B. Deliberations about clinical pharmacogenetic testing in pediatric oncology. Per Med 2021;18:399-405. [PMID: 33973801 DOI: 10.2217/pme-2020-0120] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]

Number

Cited by Other Article(s)

Conyers R, Halman A, Moore C, Stenta T, Felmingham B, Collier L, Khatri D, Spelman T, Williams E, Dyas R, Kotecha RS, Jessop S, Mateos MK, Swen J, Elliott DA. Minimising Adverse Drug Reactions and Verifying Economic Legitimacy-Pharmacogenomics Implementation in Children (MARVEL- PIC): protocol for a national randomised controlled trial of pharmacogenomics implementation. BMJ Open 2024;14:e085115. [PMID: 38760050 PMCID: PMC11103189 DOI: 10.1136/bmjopen-2024-085115] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/06/2024] [Accepted: 04/18/2024] [Indexed: 05/19/2024] Open

Abstract

INTRODUCTION

DNA-informed prescribing (termed pharmacogenomics, PGx) is the epitome of personalised medicine. Despite international guidelines existing, its implementation in paediatric oncology remains sparse.

METHODS AND ANALYSIS

Minimising Adverse Drug Reactions and Verifying Economic Legitimacy-Pharmacogenomics Implementation in Children is a national prospective, multicentre, randomised controlled trial assessing the impact of pre-emptive PGx testing for actionable PGx variants on adverse drug reaction (ADR) incidence in patients with a new cancer diagnosis or proceeding to haematopoetic stem cell transplant. All ADRs will be prospectively collected by surveys completed by parents/patients using the National Cancer Institute Pediatric Patient Reported [Ped-PRO]-Common Terminology Criteria for Adverse Events (CTCAE) (weeks 1, 6 and 12). Pharmacist will assess for causality and severity in semistructured interviews using the CTCAE and Liverpool Causality Assessment Tool. The primary outcome is a reduction in ADRs among patients with actionable PGx variants, where an ADR will be considered as any CTCAE grade 2 and above for non-haematological toxicities and any CTCAE grade 3 and above for haematological toxicities Cost-effectiveness of pre-emptive PGx (secondary outcome) will be compared with standard of care using hospital inpatient and outpatient data along with the validated Childhood Health Utility 9D Instrument. Power and statistics considerations: A sample size of 440 patients (220 per arm) will provide 80% power to detect a 24% relative risk reduction in the primary endpoint of ADRs (two-sided α=5%, 80% vs 61%), allowing for 10% drop-out.

ETHICS AND DISSEMINATION

The ethics approval of the trial has been obtained from the Royal Children's Hospital Ethics Committee (HREC/89083/RCHM-2022). The ethics committee of each participating centres nationally has undertaken an assessment of the protocol and governance submission.

TRIAL REGISTRATION NUMBER

NCT05667766.

Collapse

Affiliation(s)

Rachel Conyers Cancer Therapies Group, Murdoch Children's Research Institute, Parkville, Victoria, Australia Department of Paediatrics, The University of Melbourne, Melbourne, Victoria, Australia Children's Cancer Centre, The Royal Children's Hospital, Melbourne, Victoria, Australia
Andreas Halman Cancer Therapies Group, Murdoch Children's Research Institute, Parkville, Victoria, Australia Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
Claire Moore Cancer Therapies Group, Murdoch Children's Research Institute, Parkville, Victoria, Australia Department of Paediatrics, The University of Melbourne, Melbourne, Victoria, Australia
Tayla Stenta Cancer Therapies Group, Murdoch Children's Research Institute, Parkville, Victoria, Australia
Ben Felmingham Cancer Therapies Group, Murdoch Children's Research Institute, Parkville, Victoria, Australia
Lane Collier Cancer Therapies Group, Murdoch Children's Research Institute, Parkville, Victoria, Australia Department of Paediatrics, The University of Melbourne, Melbourne, Victoria, Australia
Dhrita Khatri Cancer Therapies Group, Murdoch Children's Research Institute, Parkville, Victoria, Australia
Tim Spelman Department of Health Services Research and Implementation Science, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia Burnet Institute, Melbourne, Victoria, Australia
Elizabeth Williams Cancer Therapies Group, Murdoch Children's Research Institute, Parkville, Victoria, Australia
Roxanne Dyas Cancer Therapies Group, Murdoch Children's Research Institute, Parkville, Victoria, Australia
Rishi S Kotecha Perth Children's Hospital, Nedlands, Western Australia, Australia Curtin University Curtin Medical School, Bentley, Western Australia, Australia
Sophie Jessop Michael Rice Centre for Haematology and Oncology, Women's and Children's Hospital Adelaide, North Adelaide, South Australia, Australia
Marion K Mateos Sydney Children's Hospitals Network, Randwick, New South Wales, Australia
Jesse Swen Leids Universitair Medisch Centrum, Leiden, Netherlands
David A Elliott Cancer Therapies Group, Murdoch Children's Research Institute, Parkville, Victoria, Australia Department of Paediatrics, The University of Melbourne, Melbourne, Victoria, Australia

Collapse

Subasri M, Cressman C, Arje D, Schreyer L, Cooper E, Patel K, Ungar WJ, Barwick M, Denburg A, Hayeems RZ. Translating Precision Health for Pediatrics: A Scoping Review. CHILDREN (BASEL, SWITZERLAND) 2023;10:897. [PMID: 37238445 PMCID: PMC10217253 DOI: 10.3390/children10050897] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/20/2023] [Revised: 05/09/2023] [Accepted: 05/11/2023] [Indexed: 05/28/2023]

Affiliation(s)

Mathushan Subasri Child Health Evaluative Sciences Program, The Hospital for Sick Children Research Institute, Toronto, ON M5G 1X8, Canada; (M.S.); (C.C.); (D.A.); (L.S.); (E.C.); (K.P.); (W.J.U.); (M.B.); (A.D.)
Celine Cressman Child Health Evaluative Sciences Program, The Hospital for Sick Children Research Institute, Toronto, ON M5G 1X8, Canada; (M.S.); (C.C.); (D.A.); (L.S.); (E.C.); (K.P.); (W.J.U.); (M.B.); (A.D.)
Danielle Arje Child Health Evaluative Sciences Program, The Hospital for Sick Children Research Institute, Toronto, ON M5G 1X8, Canada; (M.S.); (C.C.); (D.A.); (L.S.); (E.C.); (K.P.); (W.J.U.); (M.B.); (A.D.) Department of Paediatrics, University of Toronto, Toronto, ON M5G 1X8, Canada
Leighton Schreyer Child Health Evaluative Sciences Program, The Hospital for Sick Children Research Institute, Toronto, ON M5G 1X8, Canada; (M.S.); (C.C.); (D.A.); (L.S.); (E.C.); (K.P.); (W.J.U.); (M.B.); (A.D.)
Erin Cooper Child Health Evaluative Sciences Program, The Hospital for Sick Children Research Institute, Toronto, ON M5G 1X8, Canada; (M.S.); (C.C.); (D.A.); (L.S.); (E.C.); (K.P.); (W.J.U.); (M.B.); (A.D.)
Komal Patel Child Health Evaluative Sciences Program, The Hospital for Sick Children Research Institute, Toronto, ON M5G 1X8, Canada; (M.S.); (C.C.); (D.A.); (L.S.); (E.C.); (K.P.); (W.J.U.); (M.B.); (A.D.)
Wendy J. Ungar Child Health Evaluative Sciences Program, The Hospital for Sick Children Research Institute, Toronto, ON M5G 1X8, Canada; (M.S.); (C.C.); (D.A.); (L.S.); (E.C.); (K.P.); (W.J.U.); (M.B.); (A.D.) Institute for Health Policy, Management and Evaluation, University of Toronto, Toronto, ON M5T 3M6, Canada
Melanie Barwick Child Health Evaluative Sciences Program, The Hospital for Sick Children Research Institute, Toronto, ON M5G 1X8, Canada; (M.S.); (C.C.); (D.A.); (L.S.); (E.C.); (K.P.); (W.J.U.); (M.B.); (A.D.) Institute for Health Policy, Management and Evaluation, University of Toronto, Toronto, ON M5T 3M6, Canada
Avram Denburg Child Health Evaluative Sciences Program, The Hospital for Sick Children Research Institute, Toronto, ON M5G 1X8, Canada; (M.S.); (C.C.); (D.A.); (L.S.); (E.C.); (K.P.); (W.J.U.); (M.B.); (A.D.) Institute for Health Policy, Management and Evaluation, University of Toronto, Toronto, ON M5T 3M6, Canada Division of Haematology/Oncology, Hospital for Sick Children, University of Toronto, Toronto, ON M5G 1X8, Canada
Robin Z. Hayeems Child Health Evaluative Sciences Program, The Hospital for Sick Children Research Institute, Toronto, ON M5G 1X8, Canada; (M.S.); (C.C.); (D.A.); (L.S.); (E.C.); (K.P.); (W.J.U.); (M.B.); (A.D.) Institute for Health Policy, Management and Evaluation, University of Toronto, Toronto, ON M5T 3M6, Canada

Collapse

Mowbray C, Turner J, Gai J, Jacobs S. Comfort with Pharmacogenetic Testing Amongst Pediatric Oncology Providers and Their Patients. JOURNAL OF PEDIATRIC HEMATOLOGY/ONCOLOGY NURSING 2022;39:168-177. [PMID: 35467433 PMCID: PMC9462430 DOI: 10.1177/10434542211055999] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 04/27/2023]